MRK

Merck & Company Inc. Common Stock (new) (MRK)

Stock · NYSE · Health Care

$148.35as of 8/28/2026

AI Market Commentary

AI-generated

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

August 30, 2026

MRK Among Dow Jones Movers as Ebola Emergency Declared. Merck shares were active in today's Dow Jones session after the World Health Organization confirmed the Ebola outbreak in the Democratic Republic of Congo still meets the criteria for a Public Health Emergency of International Concern. Merck has been developing Ebola treatments, including the antiviral mAb114, which received FDA approval in 2019. The company was also flagged in a list of healthcare stocks with notable options activity, adding to intraday interest. With shares trading near $118.76 support and a trailing P/E of 103.9, the stock remains well above its 52-week low of $77.58.

Active signals

Support level
$117.47
Industry
Biotechnology: Pharmaceutical Preparations

About MRK

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. Th…

Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Employees
73,000

Fundamentals

1-day range
$145.75$149.01
Market cap
$315.57B
P/E (trailing)
103.86
P/E (forward)
15.55
EPS (trailing)
$1.25
Dividend yield
2.87%
Beta
0.22
Avg. volume
10.94M
Ex-dividend date
September 15, 2026
Dividend pay date
October 7, 2026
52-week range
$77.58$156.92
Next earnings: October 29, 2026 · EPS estimate $2.21confirmed

How Merck & Company Inc. Common Stock (new) Makes Money

Where the revenue actually goes — FY2025 annual results

market-wall.comTotalRevenue$65.01BNet Income$18.25B (28%)Cost of Revenue$16.38B (25%)R&D$15.79B (24%)SG&A$10.73B (17%)Tax$2.80B (4%)Other$1.05B (2%)MRK

Source: 10-K filed Feb 24, 2026 · via SEC EDGAR / Finnhub

Forecasts

26 analyst ratings

Buy 69%
Hold 31%
Sell 0%
1-year price forecast
High
$186
+25.4%
Median
$150
+1.1%
Low
$105
-29.2%

Merck & Company Inc. Common Stock (new) Competitors

Chosen by industry and closest market cap.

  • MRK
    Merck & Company Inc. Common Stock (new)
    $148.32
    ▼ 0.82%
    Market cap $315.57BP/E 103.86
    $77.58$156.92
  • NVS
    Novartis AG Common Stock
    $153.79
    ▼ 0.56%
    Market cap $293.23BP/E 21.95
    $96.03$131.5
  • AZN
    AstraZeneca PLC Ordinary Shares
    $162.69
    ▼ 1.11%
    Market cap $244.97BP/E 23.44
    $10,784$15,730
  • NVO
    Novo Nordisk A/S Common Stock
    $45.6
    ▼ 1.43%
    Market cap $208.51BP/E 11.40
    $224.25$409.95
  • ABBV
    AbbVie Inc. Common Stock
    $255.56
    ▼ 1.01%
    Market cap $433.04BP/E 70.24
    $190.75$267.47
  • ABT
    Abbott Laboratories Common Stock
    $112.42
    ▲ 0.74%
    Market cap $185.36BP/E 35.52
    $81.97$137.49
  • PFE
    Pfizer Inc. Common Stock
    $27.95
    ▼ 0.25%
    Market cap $142.66BP/E 35.19
    $23.58$28.75

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

Insider Activity

Insider Actions
Acquired
67.3K
Disposed
156.7K

Institutional Ownership

March 31, 2026

Total shares held
1.82B
Total value held
$209.80B
Institutional holders
3703
Top holders this quarter
  • Unknown225.93M
  • Unknown160.99M
  • Unknown119.33M
  • Unknown84.31M
  • Unknown59.56M
  • Unknown49.77M
  • Unknown47.63M
  • Unknown44.52M
  • Unknown30.77M
  • Unknown27.09M

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.